Business Wire

CT-INTERACTIVE-BROKERS

28.2.2022 16:02:07 CET | Business Wire | Press release

Share
Interactive Brokers Introduces Traders’ Insight Radio

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Traders’ Insight Radio , a new podcast series featuring interviews with executives, thought leaders and market experts from across the financial services industry discussing topical themes impacting global markets and trading. Listeners familiar with Traders’ Insight , Interactive Brokers’ online resource for market commentary, will recognize in-house IBKR podcast hosts providing important context around the singular viewpoints being examined during the conversations.

Intended for a broad audience including both advanced traders and novice investors, Traders’ Insight Radio explores a wide range of interesting topics for any investor and enhances the suite of offerings already available through IBKR Campus , the company’s best-in-class educational resource. Recent and upcoming podcasts will feature conversations on the impact of artificial intelligence (AI) on markets, opportunities in foreign securities and views on cryptocurrency as the new digital asset class. For retail investors just starting out or advanced traders seeking to expand their knowledge base, IBKR Campus includes courses and content on trading, markets and current events, as well as overviews dedicated to IBKR’s products and trading platforms – and now, notable podcast interviews.

“We continue to focus on providing investors with the educational tools needed to improve their understanding of financial markets and trading,” said Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers. “Traders’ Insight Radio complements the resources already available through IBKR Campus and is a new and entertaining way all investors can easily access and benefit from expertise across the finance industry.”

The series was introduced in January and early episodes include a two-part interview with Thomas Peterffy, Founder and Chairman of Interactive Brokers Group, discussing his early trading days as an options market maker and how he successfully introduced technology to the trading floor. Listeners will benefit from Mr. Peterffy’s perspective on a variety of subjects such as cryptocurrency, monetary policy and the impact of rising rates and inflation on the economy, while hearing anecdotes from his storied career. To listen to Mr. Peterffy’s podcast interviews, please visit:

Part 1: "You Mean You Don't Have to Know Anything to Do This?"

Part 2: "Mr. Sosnick, I Do Find You Increasingly Useless"

The latest episodes of Traders’ Insight Radio are available for free on the Traders’ Insight blog, through Interactive Brokers’ trading platforms including Trader Workstation, Client Portal and IBKR Mobile and popular podcasting services including Apple Podcast, Google Podcast, Podbean and Spotify.

For the full suite of free IBKR Campus resources, please see below and visit ibkr.com/campus .

Traders' Academy : Investors can improve their understanding of the products, tools and markets available through Interactive Brokers’ Trader Workstation, Client Portal, IBKR Mobile and TWS API applications.

IBKR Webinars : Investors can watch, listen and learn about current market topics and IBKR tools through live and recorded webinars.

Traders' Insight : Investors can watch, read or listen to market commentary from more than 70 industry professionals, including the new Traders’ Insight Radio.

IBKR Quant : A blog intended for quantitative professionals with an interest in programming, deep learning, IBKR API, AI, Blockchain and other transformative technologies influencing modern markets.

Student Trading Lab : A free online resource for educators looking to blend finance or computer science classwork with real-world trading experience.

About Interactive Brokers Group, Inc.:

Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 135 markets in numerous countries and currencies, from a single IBKR Integrated Investment Account to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its February 26, 2021, Best Online Broker Review.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release

Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye